Envestnet Asset Management Inc. Purchases 24,726 Shares of Hims & Hers Health, Inc. $HIMS

Envestnet Asset Management Inc. boosted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 41.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 83,844 shares of the company’s stock after buying an additional 24,726 shares during the period. Envestnet Asset Management Inc.’s holdings in Hims & Hers Health were worth $4,180,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Northern Trust Corp increased its holdings in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after buying an additional 397,310 shares in the last quarter. Nuveen LLC bought a new stake in Hims & Hers Health during the 1st quarter worth approximately $58,403,000. BIT Capital GmbH increased its holdings in Hims & Hers Health by 7.4% during the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after purchasing an additional 112,949 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Hims & Hers Health by 3.7% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,216,499 shares of the company’s stock valued at $35,948,000 after purchasing an additional 43,525 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Hims & Hers Health by 10.7% in the first quarter. Alliancebernstein L.P. now owns 812,123 shares of the company’s stock worth $23,998,000 after purchasing an additional 78,756 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HIMS shares. KeyCorp assumed coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating for the company. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, Truist Financial dropped their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and a consensus target price of $45.27.

Insider Activity

In other news, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $694,324.50. Following the transaction, the insider directly owned 297,139 shares in the company, valued at $15,005,519.50. This trade represents a 4.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Monday, August 18th. The stock was sold at an average price of $45.06, for a total value of $5,773,402.62. Following the sale, the chief executive officer directly owned 89,521 shares of the company’s stock, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 712,336 shares of company stock valued at $37,611,319 in the last 90 days. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Down 7.7%

Shares of NYSE HIMS opened at $36.00 on Friday. Hims & Hers Health, Inc. has a 1 year low of $19.15 and a 1 year high of $72.98. The firm’s 50-day moving average is $50.86 and its 200-day moving average is $51.16. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $8.20 billion, a PE ratio of 66.67, a price-to-earnings-growth ratio of 7.77 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same period last year, the firm earned $0.32 earnings per share. The company’s quarterly revenue was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.